Assembly Biosciences (ASMB) Price & Analysis

Compare

580 Followers

ASMB Stock Chart & Stats

$36.18

-$0.45(-2.59%)

At close: Jan 08 4:00 PM EST

$36.18

-$0.45(-2.59%)

Day’s Range― - ―

52-Week Range$7.75 - $39.71

Previous CloseN/A

Volume7.37K

Average Volume (3M)164.41K

Market Cap

$557.71M

Enterprise Value$66.63M

Total Cash (Recent Filing)$232.56M

Total Debt (Recent Filing)$2.75M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Mar 05, 2026

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding15,817,140

10 Day Avg. Volume178,321

30 Day Avg. Volume164,409

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.84

Price to Sales (P/S)3.32

P/FCF Ratio-1.85

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue1.79

Enterprise Value/Gross Profit9.82

Enterprise Value/Ebitda-1.60

Forecast

1Y Price Target

$41.75

Price Target Upside15.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DataInterim Phase 1b data reinforce ABI-5366’s best-in-class potential and support advancement toward Phase 2.

Market OpportunityA once-monthly oral treatment could redefine treatment paradigms and support a ~$1B U.S. market opportunity.

Strategic PartnershipAssembly's strategic partnership with Gilead Sciences offers opt-in optionality, milestone funding, and a 40% U.S. profit-share structure.

Bears Say

Clinical Development RiskRisks that could price target achievement include clinical development risk.

Commercial Adoption RiskRisks that could price target achievement include commercial adoption risk.

Regulatory DelaysRisks that could price target achievement include manufacturing or regulatory delays.

Assembly Biosciences News

Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Assembly Biosciences (ASMB) with a $50 price target...

1d ago

ASMB

GILD

Gilead exercises option to license Assembly helicase-primase inhibitor programs

Gilead (GILD) and Assembly Biosciences (ASMB), announced Gilead has exercised its combined option to exclusively license Assembly Bio’s...

1d ago

ASMB

GILD

Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials

Assembly Biosciences (ASMB) announced interim results from two Phase 1b studies of its investigational long-acting herpes simplex virus...

15d ago

ASMB

GILD

Gilead Partnership and Positive HSV Data De‑Risk Assembly Biosciences, Supporting Buy Rating and $50 Price Target

Assembly Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

1d ago

ASMB

Assembly Biosciences Completes Key Phase 1a Study on ABI-6250

Assembly Biosciences Inc ($ASMB) announced an update on their ongoing clinical study. Assembly Biosciences Inc. has recently completed...

9d ago

ASMB

Positive Buy Rating for Assembly Biosciences Driven by Promising HSV-2 Program and Strategic Partnerships

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Assembly Biosciences, retaining the price target of...

14d ago

ASMB

Assembly Biosciences Reports Positive Phase 1b Results

The latest announcement is out from Assembly Biosciences ( ($ASMB) ). On December 8, 2025, Assembly Biosciences announced...

15d ago

ASMB

Assembly Biosciences price target raised to $40 from $29 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $40 from $29 and...

1M ago

ASMB

Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences, with...

1M ago

ASMB

Assembly Biosciences Inc. Reports Q3 2025 Earnings

Assembly Biosciences Inc ( ($ASMB) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

ASMB

Assembly Biosciences reports Q3 EPS (72c), consensus (65c)

Reports Q3 revenue $10.79M, consensus $9.32M. “Our third quarter was marked by significant progress across our pipeline and...

1M ago

ASMB

Assembly Biosciences announces Phase 1b data for ABI-4334

Assembly Biosciences (ASMB) announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator, CAM, ABI-4334 featured...

2M ago

ASMB

ASMB Earnings this Week: How Will it Perform?

Assembly Biosciences Inc (ASMB) is scheduled to report 3rd quarter earnings on 11/06/2025. Regarding Q3 estimates, Wall Street...

2M ago

ASMB

Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179

Assembly Biosciences Inc (($ASMB)) announced an update on their ongoing clinical study. Study Overview: Assembly Biosciences Inc. is...

2M ago

ASMB

ASMB FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is $557.71M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Mar 05, 2026 which is in 72 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on Nov 10, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.821 by $0.101.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.86.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 15,817,140 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.821. Following the earnings report the stock price went up 3.305%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in ASMB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Assembly Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.94%

Trailing 12-Months

Asset Growth

-29.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc. (ASMB) is a biotechnology company focused on developing innovative therapies for viral diseases, primarily targeting hepatitis B virus (HBV) infections. The company operates in the biopharmaceutical sector and is dedicated to advancing its proprietary drug candidates aimed at eradicating HBV and addressing other chronic viral infections. Assembly Biosciences leverages its expertise in virology and immunology to create therapies that can potentially cure these conditions.

Assembly Biosciences (ASMB) Earnings & Revenues

Historic Earnings Reports

ASMB Stock 12 Month Forecast

Average Price Target

$41.75

▲(15.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.89,35.12923076923077,36.36846153846154,37.60769230769231,38.846923076923076,40.08615384615385,41.325384615384614,42.56461538461539,43.80384615384615,45.043076923076924,46.28230769230769,47.52153846153846,48.76076923076923,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.89,34.494615384615386,35.09923076923077,35.70384615384616,36.308461538461536,36.91307692307692,37.51769230769231,38.12230769230769,38.72692307692308,39.331538461538464,39.93615384615384,40.54076923076923,41.145384615384614,{"y":41.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.89,34.206153846153846,34.52230769230769,34.83846153846154,35.15461538461538,35.47076923076923,35.786923076923074,36.10307692307693,36.41923076923077,36.73538461538462,37.05153846153846,37.36769230769231,37.683846153846154,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.89,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >